ES2347249T3 - Una proteina implicada en el cancer de ovario. - Google Patents

Una proteina implicada en el cancer de ovario. Download PDF

Info

Publication number
ES2347249T3
ES2347249T3 ES04769011T ES04769011T ES2347249T3 ES 2347249 T3 ES2347249 T3 ES 2347249T3 ES 04769011 T ES04769011 T ES 04769011T ES 04769011 T ES04769011 T ES 04769011T ES 2347249 T3 ES2347249 T3 ES 2347249T3
Authority
ES
Spain
Prior art keywords
polypeptide
antibody
cdcp1
agent
ovarian cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04769011T
Other languages
English (en)
Spanish (es)
Inventor
Nicola Anne Burgess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29595617&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2347249(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB SA filed Critical UCB SA
Application granted granted Critical
Publication of ES2347249T3 publication Critical patent/ES2347249T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Biophysics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
ES04769011T 2003-10-22 2004-10-22 Una proteina implicada en el cancer de ovario. Expired - Lifetime ES2347249T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0324656A GB0324656D0 (en) 2003-10-22 2003-10-22 A protein involved in ovarian cancer
GB0324656 2003-10-22

Publications (1)

Publication Number Publication Date
ES2347249T3 true ES2347249T3 (es) 2010-10-27

Family

ID=29595617

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04769011T Expired - Lifetime ES2347249T3 (es) 2003-10-22 2004-10-22 Una proteina implicada en el cancer de ovario.

Country Status (11)

Country Link
US (3) US20070009543A1 (enExample)
EP (1) EP1677875B1 (enExample)
JP (1) JP4764344B2 (enExample)
AT (1) ATE470478T1 (enExample)
AU (1) AU2004285339B2 (enExample)
CA (1) CA2541846A1 (enExample)
DE (1) DE602004027647D1 (enExample)
ES (1) ES2347249T3 (enExample)
GB (1) GB0324656D0 (enExample)
PL (1) PL1677875T3 (enExample)
WO (1) WO2005042102A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080008719A1 (en) * 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
US20090274619A1 (en) * 2006-01-26 2009-11-05 George Coukos Tumor vasculature markers and methods of use therof
US20130136689A1 (en) * 2007-06-05 2013-05-30 Christian Rohlff Proteins
JP2010532484A (ja) * 2007-06-29 2010-10-07 コレロジック システムズ，インコーポレイテッド 卵巣癌のための予測マーカー
TW201113037A (en) 2009-08-28 2011-04-16 Hoffmann La Roche Antibodies against CDCP1 for the treatment of cancer
TWI412375B (zh) 2009-08-28 2013-10-21 Roche Glycart Ag 人類化抗ｃｄｃｐ１抗體
EP2971259B8 (en) 2013-03-13 2018-11-21 NantEnergy, Inc. Synergistic additives for electrochemical cells with electrodeposited fuel
WO2015082446A1 (en) 2013-12-02 2015-06-11 F. Hoffmann-La Roche Ag Treatment of cancer using an anti-cdcp1 antibody and a taxane
WO2018112334A1 (en) 2016-12-16 2018-06-21 Bluefin Biomedicine, Inc. Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
US11424484B2 (en) 2019-01-24 2022-08-23 Octet Scientific, Inc. Zinc battery electrolyte additive
EP4055058A4 (en) * 2019-11-06 2023-12-06 Commonwealth Scientific and Industrial Research Organisation CUB DOMAIN-CONTAINING PROTEIN (CDCP1) BINDING PROTEINS
WO2021132427A1 (ja) 2019-12-27 2021-07-01 株式会社カイオム・バイオサイエンス 抗ｃｄｃｐ１抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5134799A (en) 1998-07-30 2000-02-21 Human Genome Sciences, Inc. 98 human secreted proteins
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
US20020142003A1 (en) * 2000-07-07 2002-10-03 Norbert Schweifer Tumor-associated antigen (B345)
WO2002004508A1 (de) 2000-07-07 2002-01-17 Boehringer Ingelheim International Gmbh Tumorassoziiertes antigen (b345), gekennzeichnet durch eine aminosäuresequenz wie in seq. id. no. 4
US6783969B1 (en) 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides
BRPI0407680A (pt) 2003-02-19 2006-03-01 Novartis Ag métodos para diagnóstico de cáncer e diminuição de metástase por células cancerosas

Also Published As

Publication number Publication date
US20130230524A1 (en) 2013-09-05
PL1677875T3 (pl) 2010-11-30
US20070009543A1 (en) 2007-01-11
CA2541846A1 (en) 2005-05-12
GB0324656D0 (en) 2003-11-26
WO2005042102A1 (en) 2005-05-12
JP2007513873A (ja) 2007-05-31
DE602004027647D1 (de) 2010-07-22
AU2004285339B2 (en) 2009-11-19
EP1677875B1 (en) 2010-06-09
US20110059088A1 (en) 2011-03-10
ATE470478T1 (de) 2010-06-15
US8263071B2 (en) 2012-09-11
US9120860B2 (en) 2015-09-01
EP1677875A1 (en) 2006-07-12
JP4764344B2 (ja) 2011-08-31
AU2004285339A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
US9120860B2 (en) Protein involved in ovarian cancer
ES2663556T3 (es) Anticuerpos frente al receptor alfa del folato y usos de los mismos
ES2394018T3 (es) Procedimientos para el diagnóstico y el tratamiento de cánceres derivados de células epiteliales
US7261892B2 (en) Methods for diagnosis and treatment of epithelial-derived cancers
AU2003249072B2 (en) PTK7 protein involvement in carcinoma
ES2625259T3 (es) Identificación de proteína asociada con carcinoma hepatocelular, glioblastoma y cáncer de pulmón
US20070142276A1 (en) Protein involved in carcinoma
ES2274220T3 (es) Diagnostico de carcinoma usando polipeptidos raig1.
US20090214540A1 (en) Protein involved in cancer
US20070141061A1 (en) Protein involved in carcinoma
GB2455634A (en) Treatment of cancer
US20070269431A1 (en) Protein Involved In Cancer
WO2006000753A2 (en) Use of flj40787, a protein involved in colon, colorectal, ovarian, lung and/or liver cancer
WO2005105143A2 (en) Vaccines and antibodies against ltk for therapy of cancers.
WO2006003427A1 (en) A protein involved in carcinoma
WO2005049066A2 (en) Use of dudulin2 for the treatment or prophylaxis of lung cancer
WO2005019257A1 (en) A protein involved in pancreatic cancer